Jennifer Spear Smith may be soft-spoken and petite, but she is loud, clear, and stands tall for one part of industry that she is clearly passionate about: continuing medical education (CME).
JENNIFER SPEAR SMITH
Executive Director, Medical Education, Wyeth
(JOHN HALPERN)
Jennifer Spear Smith may be soft-spoken and petite, but she is loud, clear, and stands tall for one part of industry that she is clearly passionate about: continuing medical education (CME).
Prior to her current position as executive director of medical education for Wyeth, Spear Smith was a CME provider and before that a professor in physiology at Indiana University and Purdue University's combined medical school program. "Medical school was just a starting point for me," says Spear Smith. "Things change so differently in medicine. There is a system, but it needs improvement so that physicians can be helping patients. That is the reason I go to work every day, to improve patient care."
Spear Smith was attracted to the pharma industry for the ample resources available to guide CME in a direction where she could "make a difference in patient care." And she already has by helping to make Wyeth one of the first pharmaceutical companies to require CME providers, after they conducted a CME activity, to measure its success.
"In 10 years, I hope I am still involved in managing education of physicians where it's my goal to continue in a position that ultimately helps patient care," Spear Smith says. "A pharma company is in the perfect position to make a change with how they conduct business and really gear it toward patient care. When we can do that we will have really revolutionized the business."
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.